Ab­b­Vie hus­tles its uni­corn drug Ro­va-T in­to the clin­ic in com­bo with Bris­tol's Op­di­vo

Ab­b­Vie is wast­ing lit­tle time in get­ting its new­ly ac­quired drug Ro­va-T in­to the clin­ic for small cell lung can­cer in com­bi­na­tion with a check­point ther­a­py. And its can­cer team is go­ing with the mar­ket leader, Bris­tol-My­ers Squibb, and its megablock­buster Op­di­vo as well as Yer­voy.

Gary Gor­don, the vice pres­i­dent for on­col­o­gy at Ab­b­Vie, told me at AS­CO re­cent­ly that he was work­ing on an I/O com­bo pact, part of Ab­b­Vie’s am­bi­tious plans to piv­ot in­to reg­is­tra­tion stud­ies that would po­si­tion the com­pa­ny for a pos­si­ble near-term ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER